Axovant Sciences (AXON) Receiving Somewhat Favorable Media Coverage, Study Shows
Media headlines about Axovant Sciences (NASDAQ:AXON) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axovant Sciences earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.2563605603023 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Axovant Sciences Ltd. (AXON) Can’t Burn Your Short Portfolio. Just Reaches 52 Week Low – Reurope (reurope.com)
- Trending Stocks Analysis Report: Axovant Sciences Ltd. (NYSE:AXON), HMS Holdings Corp. (NASDAQ:HMSY) – The Oracle Examiner (oracleexaminer.com)
- Hot Stock under Review – Axovant Sciences Ltd (NASDAQ: AXON) – Alpha Beta Stock (alphabetastock.com)
- Under Analysts’ Radar: Axovant Sciences Ltd. (AXON) – ExpertGazette (expertgazette.com)
- Axovant Sciences Ltd. (AXON) – Hot Healthcare stock Alert – Nasdaq Fortune (press release) (nasdaqfortune.com)
AXON has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Axovant Sciences in a research note on Thursday, October 19th. Chardan Capital reaffirmed a “sell” rating and set a $3.00 price objective on shares of Axovant Sciences in a research note on Friday, November 3rd. BidaskClub downgraded shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Robert W. Baird reaffirmed a “hold” rating and set a $6.00 price objective on shares of Axovant Sciences in a research note on Wednesday, November 1st. Finally, Cowen downgraded shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research note on Friday, January 12th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $13.61.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/12/axovant-sciences-axon-receiving-somewhat-favorable-media-coverage-study-shows.html.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.